Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.

At this year’s AACR Annual Meeting Constellation will be represented by one oral presentation and four posters encompassing work on chromatin biology.

Patrick Trojer will be giving a talk entitled “Targeting Histone Lysine Methylation in Cancer”, in Saturday’s 11:45 am session, room 28 A-C.

In addition, the following posters will be presented:

Defining the determinants of sensitivity and resistance to BET bromodomain inhibition

Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CP1203 in bortezomib-resistant mantle cell lymphoma

Inhibition of the histone methyl transferase EZH2 causes viability defects in multiple myeloma

CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models